title: Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.
abstract: BACKGROUND
  Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections.
  
  
  OBJECTIVE
  To compare the efficacy of different 1-week moxifloxacin-based Helicobacter pylori eradication regimens.
  
  
  METHODS
  One hundred and twenty H. pylori-positive subjects were randomized to receive moxifloxacin (400 mg/day), moxifloxacin (400 mg/day) and lansoprazole (30 mg/day) or moxifloxacin (400 mg/day), lansoprazole (30 mg/day) and clarithromycin (500 mg b.d.). H. pylori status was reassessed 6 weeks after the end of therapy, and both intention-to-treat and per protocol analyses were performed.
  
  
  RESULTS
  One hundred and nineteen of the 120 patients completed the study. H. pylori eradication was achieved in 22.5% of patients treated with moxifloxacin, in 33.3% of subjects treated with moxifloxacin and lansoprazole and in 90% of patients treated with moxifloxacin, clarithromycin and lansoprazole.
  
  
  CONCLUSIONS
  Mono and dual moxifloxacin-based therapies are not acceptable for H. pylori eradication; conversely, moxifloxacin-based triple therapy may be considered as a new, effective, first-line therapy option.
authors.affiliation: Internal Medicine Department, Gemelli Hospital, Rome, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Di Caro
authors.forename: V
authors.initials: V
authors.lastname: Ojetti
authors.forename: M A
authors.initials: MA
authors.lastname: Zocco
authors.forename: F
authors.initials: F
authors.lastname: Cremonini
authors.forename: F
authors.initials: F
authors.lastname: Bartolozzi
authors.forename: M
authors.initials: M
authors.lastname: Candelli
authors.forename: A
authors.initials: A
authors.lastname: Lupascu
authors.forename: E C
authors.initials: EC
authors.lastname: Nista
authors.forename: G
authors.initials: G
authors.lastname: Cammarota
authors.forename: A
authors.initials: A
authors.lastname: Gasbarrini
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001372:Aza Compounds; D017291:Clarithromycin / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D024841:Fluoroquinolones; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010349:Patient Compliance; D011804:Quinolines; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D004338:Drug Combinations; D024841:Fluoroquinolones; D011804:Quinolines; D064747:Lansoprazole; D017291:Clarithromycin; D009853:Omeprazole; D000077266:Moxifloxacin